Aclarion Announces First Commercial Agreement in Michigan

Core Insights - Aclarion, Inc. has established a commercial agreement with Sheridan Community Hospital to introduce Nociscan, a healthcare technology solution for chronic low back pain, to central Michigan [1][3] - Nociscan is the first evidence-supported SaaS platform that helps physicians noninvasively distinguish between painful and nonpainful discs in the lumbar spine, utilizing biomarkers and augmented intelligence algorithms [2][4] Company Overview - Aclarion is focused on addressing the chronic low back pain market with its Nociscan platform, which leverages Magnetic Resonance Spectroscopy (MRS) and proprietary signal processing techniques to optimize clinical treatments [4] - The Nociscan solution quantifies chemical biomarkers associated with disc pain and provides critical insights when used alongside other diagnostic tools, enhancing treatment strategies for physicians [4] Market Context - Chronic low back pain affects approximately 266 million people globally, highlighting the significant healthcare challenge that Aclarion aims to address with its innovative technology [2] - The introduction of Nociscan in markets like Sheridan is a step towards broader payer coverage in the US, following recent insurance coverage announcements in the UK [3]